A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2016
At a glance
- Drugs GC 1109 (Primary)
- Indications Anthrax
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Green Cross
- 24 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
- 24 Feb 2016 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.
- 27 Jun 2013 Planned End Date changed from 1 Nov 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.